Germany Pharmaceuticals Market To Reach $151.51 Billion By 2033

June 2025 | Report Format: Electronic (PDF)

Germany Pharmaceuticals Market Growth & Trends

The Germany pharmaceuticals market size is estimated to reach USD 151.51 billion by 2033, registering to grow at a CAGR of 5.31% from 2025 to 2033 according to a new report by Grand View Research, Inc. Factors such as the rising prevalence of acute and chronic diseases and increasing R&D expenditure by pharmaceutical companies are expected to drive the market.

Furthermore, rising clinical trials and approval of novel immune-suppressive therapies are anticipated to propel market growth. For instance, in June 2020, Sandoz International GmbH launched Dailiport capsules (generic tacrolimus) in Germany and other European countries. Dailiport capsules are indicated for adult kidney and liver transplant patients.

In addition, the export of pharmaceutical products by pharmaceutical companies in Germany to various countries is expected to fuel market growth. For instance, according to Germany Trade and Invest, in China, 22.0% of imported pharmaceutical products are from German companies.

Key players entering into strategic initiatives such as partnership, licensing, acquisition, and collaboration to expand and strengthen their regional presence is expected to boost the market growth. For instance, in November 2019, Bristol-Myers Squibb Company acquired Celgene Corporation. This acquisition was aimed at helping the company expand its oncology portfolio worldwide and develop innovative medicines.

In addition, rising funds by organizations for the development of pipeline drugs are anticipated to accelerate market growth. For instance, in January 2019, Atriva Therapeutics GmbH closed its series A financing led by Meneldor and High-Tech Gründerfonds GmbH (HTGF) for its lead drug candidate ATR-002. This drug candidate is developed against influenza infection and other respiratory infections.

Various other organizations, such as the European Cancer Organisation (ECCO), European Cancer Patient Coalition (ECPC), and European Organisation for Research and Treatment of Cancer (EORTC) provide funds for cancer research programs and treatment plans.

Furthermore, increasing the availability of generic drugs at a lower price is expected to boost the market growth. For instance, in July 2019, Sandoz of Novartis AG launched a generic version of gefitinib for locally advanced or metastatic NSCLC. The launch of the generic version is estimated to increase the number of patients treated due to the favorable cost of the drug.

Request a free sample copy or view report summary: Germany Pharmaceuticals Market Report

Germany Pharmaceuticals Market Report Highlights

Conventional drugs (small molecules) dominated the market with a revenue share of 54.74% in 2024.
The branded segment dominated the Germany pharmaceutical industry with a revenue share of 66.86% in 2024
The prescription segment dominated the market with a revenue share of 86.76% in 2024.
The cancer segment dominated the market with a revenue share of 18.06% in 2024.
The oral segment dominated the market with a revenue share of 57.53% in 2024.
The adult segment dominated the market with a revenue share of 62.84% in 2024
The hospital pharmacy segment dominated the market with a revenue share of 53.53% in 2024

Germany Pharmaceuticals Market Segmentation

Grand View Research has segmented the Germany pharmaceuticals market based on molecule type, product, type, disease, route of administration, age group, and distribution channel:

Germany Pharmaceuticals Molecule Type Outlook (Revenue, USD Billion, 2021 - 2033)